替沙格韦单抗和西加韦单抗用于预防 2019 年冠状病毒病的暴露前预防后的心血管结局：基于人群的倾向评分匹配队列研究。
Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study.
机构信息
Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH, USA.
出版信息
Clin Infect Dis. 2023 Apr 17;76(8):1500-1503. doi: 10.1093/cid/ciac894.
Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
替沙格韦单抗和西加韦单抗治疗与一项 3 期临床试验的事后分析中较高的心血管事件发生率相关。在这项大型基于人群的倾向评分匹配研究中，我们发现替沙格韦单抗和西加韦单抗给药后 90 天内，包括有预先存在心血管疾病的患者，心血管事件风险没有增加。
Zotero 插件